MRX-4

N/A

Report date: 2026/05/15 20:01:45
NME

Base Information

Drug NameMRX-4
Drug Alias NameMRX-4-Akari Therapeutics
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCytosolic phospholipase A2 inhibitors
TargetsCytosolic phospholipase A2
Therapy Area/IndicationsComplicated Skin and Soft Tissue InfectionsRhinitis, AllergicGram-Positive Bacterial Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesAkashi Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesShanghai MicuRx Pharmaceutical Co Ltd
Inactive CompaniesAkashi Therapeutics Inc
Active IndicationsComplicated Skin and Soft Tissue InfectionsGram-Positive Bacterial Infections
Inactive IndicationsRhinitis, Allergic

Other Information

ATC CodeN/A
Related LinksN/A